checkAd

    AddLife - aus Schweden - 500 Beiträge pro Seite

    eröffnet am 21.08.18 20:21:01 von
    neuester Beitrag 19.02.19 08:37:08 von
    Beiträge: 4
    ID: 1.286.811
    Aufrufe heute: 0
    Gesamt: 545
    Aktive User: 0

    ISIN: SE0014401378 · WKN: A2P4TH · Symbol: 1AD1
    8,6900
     
    EUR
    +2,06 %
    +0,1750 EUR
    Letzter Kurs 06.05.24 Frankfurt

    Werte aus der Branche Gesundheitswesen

    WertpapierKursPerf. %
    5,2500+157,35
    0,7400+36,63
    0,7643+27,81
    3,7900+20,70
    7,0000+15,32
    WertpapierKursPerf. %
    1,4200-16,96
    3,4400-20,92
    1,4100-21,23
    2,5600-24,48
    2,4100-51,51

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 21.08.18 20:21:01
      Beitrag Nr. 1 ()
      Idee von Rob Vinall, beliefert Medtech und Labtech
      Avatar
      schrieb am 24.01.19 12:12:46
      Beitrag Nr. 2 ()
      heute in Stockholm ein paar für SEK 231 gekauft
      2 Antworten
      Avatar
      schrieb am 29.01.19 08:41:36
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 59.700.642 von R-BgO am 24.01.19 12:12:46
      hatte ich übersehen;
      heute kam Mitteilung über KE 7:1, u.a. für das hier:


      AddLife signs agreement with Wellspect HealthCare on acquisition of business in surgery and respiration

      19.12.2018 - 19:30

      The Life Science group AddLife signed an agreement today with Wellspect HealthCare on the acquisition of its business in the product areas surgery and respiration. Under the agreement, AddLife is acquiring a number of market-leading niche products with associated rights and customer agreements in several geographic markets. The business has sales of about EUR 17 million, with eight markets in Europe and Australia accounting for more than 90 percent of sales. The acquisition is expected to be completed during the first quarter of 2019.

      AddLife is continuing its growth by acquiring market-leading niche products in the areas of surgery and respiration, including the brands Bellovac, Medena and KilRoid. The part of the business that AddLife is now acquiring was originally part of Astra Tech. The business will primarily be integrated into AddLife’s subsidiaries Mediplast and Biomedica during the first quarter of 2019. The total purchase consideration for the business, which primarily includes product rights, inventories and existing customer and supplier contracts, is EUR 18 million.

      - “We continue to pursue our growth strategy – acquiring market-leading niche companies and businesses, along with our international expansion. We are now expanding our offering of our own brands which complement our subsidiaries’ existing range of products in surgery and respiration products. Together, our two most recently announced acquisitions add over SEK 800 million in annual sales and we have substantially expanded our market presence in selected niches,” says Kristina Willgård, CEO of AddLife AB.

      - “We are extremely pleased that in the future, ownership of our product range in surgery and respiration will pass to such well-established companies as Mediplast and Biomedica, which to a much greater degree than we do have the necessary focus and expertise to optimally develop the business,” says Svenn Poulsen, Group Vice President, Wellspect HealthCare.

      The agreement for the acquisition of the business in Wellspect Healthcare is taking place less than one month after the acquisition of the Austrian company Biomedica, which has sales of about EUR 65 million and engages in business in 13 markets in Central and Eastern Europe. The deal enables AddLife to make additional inroads into new geographic markets, primarily Australia, which accounts for about 30 percent of sales in the acquired business operations.

      Stockholm, 19 December 2018
      AddLife AB (publ)
      1 Antwort
      Avatar
      schrieb am 19.02.19 08:37:08
      Beitrag Nr. 4 ()
      Antwort auf Beitrag Nr.: 59.733.093 von R-BgO am 29.01.19 08:41:36
      Stücke aus KE
      wurden heute eingebucht


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      AddLife - aus Schweden